Immuneering Corp (IMRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immuneering Corp (IMRX) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.98 Million) by net assets ($227.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immuneering Corp - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Immuneering Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immuneering Corp (IMRX) total liabilities for a breakdown of total debt and financial obligations.
Immuneering Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immuneering Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MVB Financial Corp
NASDAQ:MVBF
|
-0.008x |
|
BAIRONG INC.CL.B -00002
F:6B5
|
N/A |
|
Bonduelle S.C.A.
PA:BON
|
-0.240x |
|
Edom Technology Co Ltd
TW:3048
|
-0.709x |
|
Consorcio ARA S. A. B. de C. V.
MX:ARA
|
0.017x |
|
NOCIL Limited
NSE:NOCIL
|
0.077x |
|
ICBC Turkey Bank AS
IS:ICBCT
|
1.650x |
|
Kap Industrial Holdings Ltd
JSE:KAP
|
0.023x |
Annual Cash Flow Conversion Efficiency for Immuneering Corp (2019–2024)
The table below shows the annual cash flow conversion efficiency of Immuneering Corp from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see IMRX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $41.39 Million | $-55.00 Million | -1.329x | -145.81% |
| 2023-12-31 | $90.58 Million | $-48.97 Million | -0.541x | -34.66% |
| 2022-12-31 | $109.85 Million | $-44.10 Million | -0.401x | -102.98% |
| 2021-12-31 | $155.98 Million | $-30.85 Million | -0.198x | -130.41% |
| 2020-12-31 | $-22.48 Million | $-14.62 Million | 0.650x | -4.43% |
| 2019-12-31 | $-6.53 Million | $-4.44 Million | 0.680x | -- |
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 … Read more